(IN BRIEF) Basilea Pharmaceutica has received an additional USD 30 million from BARDA to support the ongoing phase 3 development of fosmanogepix, its novel first-in-class broad-spectrum antifungal candidate. The funding was awarded after Basilea met a prespecified enrolment milestone and … Read the full press release →
Posted in Business, Financial, Government, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Administration for Strategic Preparedness and Response, agreement number 75A50124C00033, Allschwil, antifungal treatment, aspergillosis, Aspergillus, ASPR, azole-resistant strains, BAL2062, BARDA, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, Basilea Secures New BARDA Tranche After Phase 3 Enrolment Milestone, Basilea Strengthens Antifungal Pipeline Funding Under Existing BARDA Agreement, Biomedical Advanced Research and Development Authority, broad-spectrum antifungal, Candida glabrata, Candida auris, candidemia, candidiasis, David Veitch, FAST study, Fast Track Designation, FDA, first in class antifungal, FORWARD study, fosmanogepix, Fosmanogepix Development Advances With Additional USD 30 Million BARDA Support, Fusarium, HHS, immunocompromised patients, invasive aspergillosis, invasive candidiasis, invasive fungal infections, Mucorales, multidrug-resistant fungal infections, orphan drug designation, OTA, Other Transaction Agreement, Phase 3 development, QIDP, Qualified Infectious Disease Product, Scedosporium, Switzerland, U.S Department of Health and Human Services, U.S. Food and Drug Administration, United States, USD 268 million potential non-dilutive funding, USD 30 million funding, USD 93 million committed funding
(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release →
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Allschwil, antibacterial, antifungal, ASPR, BAL2062, BARDA, Basilea Pharmaceutica Ltd, Cresemba®, fosmanogepix, HHS, invasive candidiasis, invasive mold infections, multidrug-resistant Candida auris, orphan drug, Other Transaction Agreement, partnership, QIDP, Switzerland, Zevtera®
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
